Alumis (ALMS)

Executive Summary

Alumis is a clinical-stage biopharmaceutical company developing precision-engineered oral therapies for immune-mediated diseases, with a focus on its lead TYK2 inhibitor, envudeucitinib (ESK-001). The company has reported robust Phase 3 data in plaque psoriasis, positioning it as a potential best-in-class oral treatment. With a proprietary data analytics platform integrating multi-omics and clinical insights, Alumis aims to deliver superior efficacy and safety compared to conventional immunosuppressants. The company is publicly traded (NASDAQ: ALMS) with a market capitalization of approximately $2.6 billion and is advancing a late-stage pipeline targeting psoriasis and other inflammatory conditions. Alumis's key near-term catalyst is the anticipated NDA submission for envudeucitinib in plaque psoriasis, expected in the second half of 2026, following positive Phase 3 results. Additionally, ongoing Phase 2 and Phase 3 trials (NCT05739435 and NCT06846541) are exploring longer-term safety and efficacy, with top-line data from the Phase 2 trial anticipated by late 2026. The company also recently completed Phase 1 studies in hepatic and renal impairment, supporting its regulatory package. With a strong data profile and a large addressable market in psoriasis, Alumis is well-positioned to capture significant market share if approved.

Upcoming Catalysts (preview)

• H2 2026NDA submission for envudeucitinib in plaque psoriasis80% success
• Q4 2026Top-line Phase 2 data from long-term extension trial (NCT05739435)90% success
• TBDPotential partnership or licensing deal for pipeline expansion50% success